India faces a significant public health challenge as it carries one of the world's highest burdens of viral hepatitis, a group of infectious diseases that silently damage the liver and affect millions of people across the country. Despite being largely preventable and treatable, hepatitis continues to claim lives due to delayed diagnosis and limited awareness among the general population.
Understanding Viral Hepatitis
Viral hepatitis refers to liver inflammation caused by five main virus types: hepatitis A, B, C, D, and E. Among these, hepatitis B and C are particularly concerning in India as they cause chronic infections that can lead to cirrhosis, liver failure, and liver cancer over time. Unlike acute infections from hepatitis A and E, which typically resolve on their own, hepatitis B and C can persist for years without noticeable symptoms, earning them the label of "silent killers."
The hepatitis B virus is primarily transmitted through contact with infected blood or body fluids, often from mother to child during childbirth, or through unsafe medical procedures and unscreened blood transfusions. Hepatitis C spreads similarly, with injection drug use and inadequate sterilization of medical equipment being major risk factors.
India's Disease Burden
India is home to approximately 40 million people living with chronic hepatitis B and an estimated 6 to 12 million with hepatitis C. These numbers represent a substantial portion of the global hepatitis burden, making India a focal point for international health organizations working to eliminate viral hepatitis as a public health threat by 2030.
Several factors contribute to India's high hepatitis prevalence. These include:
- Large population base with varying levels of healthcare access
- Incomplete vaccination coverage, particularly in rural areas
- Reuse of medical equipment in some healthcare settings
- Limited screening programs for blood products in the past
- Low awareness about transmission routes and prevention
- Social stigma preventing people from seeking testing
The Case for Early Diagnosis
The most critical aspect of managing hepatitis is early detection. Many people live with chronic hepatitis for decades without knowing it, as the liver can continue functioning even when significantly damaged. Symptoms often only appear when the disease has progressed to advanced stages, making treatment more complicated and outcomes less favorable.
Early diagnosis allows for timely intervention with antiviral medications that can suppress the virus, prevent disease progression, and dramatically reduce the risk of liver cancer and cirrhosis. For hepatitis C, modern direct-acting antiviral drugs can cure over 95 percent of cases within 8 to 12 weeks of treatment.
Who Should Get Tested
Medical experts recommend hepatitis screening for several high-risk groups:
- Pregnant women to prevent mother-to-child transmission
- Healthcare workers exposed to blood and body fluids
- People who have received blood transfusions, especially before routine screening began
- Individuals with a history of injection drug use
- Those with multiple sexual partners
- Family members of someone with chronic hepatitis
- People with elevated liver enzymes or unexplained liver problems
Prevention Strategies
Preventing hepatitis requires a multi-pronged approach combining vaccination, safe medical practices, and public awareness. The hepatitis B vaccine has been part of India's Universal Immunization Programme since 2002, providing protection to newborns and children. However, catch-up vaccination for adults and adolescents who missed childhood immunization remains important.
Other preventive measures include ensuring safe blood transfusions, using sterile needles and medical equipment, practicing safe sex, and avoiding sharing personal items like razors or toothbrushes that might have blood on them.
Treatment Availability
India has made significant progress in making hepatitis treatment more accessible and affordable. Generic versions of antiviral medications are available at a fraction of the cost compared to many developed countries. Several government initiatives provide free or subsidized testing and treatment for hepatitis, though awareness about these programs needs improvement.
Moving Forward
Addressing India's hepatitis burden requires sustained commitment from government, healthcare providers, and communities. Expanding screening programs, improving vaccination coverage, strengthening healthcare infrastructure, and launching targeted awareness campaigns are essential steps toward reducing the disease burden.
This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you suspect you may have hepatitis or are at risk, please consult a qualified healthcare provider for proper testing and guidance.
